IRS1 and breast carcinoma: In breast cancer, miR-148a acts as a tumor suppressor via targeting IGF-IR (insulin-like growth factor-I receptor) and IRS1 (insulin receptor substrate 1) and further suppressing the downstream MAPK signaling pathway [28].